1 / 48

Chapter 6 Drug Toxicity

Chapter 6 Drug Toxicity. Adverse drug reactions Paracelsus, a Swiss physician ( 1493-1541), proposed dose-toxicity relationship“ all substances are poisons; there is none which is not a poison. The right dose differentiates a poison and remedy ” Dose-related and Non-dose related

shea-oneill
Download Presentation

Chapter 6 Drug Toxicity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 6 Drug Toxicity • Adverse drug reactions • Paracelsus, a Swiss physician ( 1493-1541), proposed dose-toxicity relationship“all substances are poisons; there is none which is not a poison. The right dose differentiates a poison and remedy” • Dose-related and Non-dose related • genetic makeup, age, underlying pathology, status of immune system.

  2. DOSE • similar to drug‘s effectiviness , drug’s toxicity e.g. lethality (mortality) also shows dose-response relationship, typical S-shape curve. • LD50 (the dosage of a substance that kills 50% of the animals over a set period of time following an acute exposure).

  3. Therapeutic index (TI)= LD50/ED50 The lower TI, the smaller the margin of safety, e.g. digoxin, 2.0

  4. probit analysis • In addition to LD50, other aspect of drug’s toxicity can be measured. • TD50 (toxic dose producing the effect in 50% of the population). • LD1/ED99 is the margin of safety or the certain safety factor

  5. comparison of drug toxicity

  6. toxicity classification

  7. cautions • based on lethality alone, false sense, • other toxicity ignored, e.g. thalidomide could be classified as slightly toxic • extrapolation, animal species differences, uncertain for human

  8. Evaluating the toxicity: timefactor • Acute basis over a 14-d period, • subchronic /subacute, 90-d period (daily given), additional information gained, target organ, major toxic effects, slower onset, • chronic , life time of animal, post-mortem examination. • Story on an antiviral drug for hepatitis- a delayed toxic reaction occurred after administration was discontinued. 5/5 died suddenly, liver failure.

  9. Important factors in these tests: Selections of dosages, species, strain of animal, rout of exposure

  10. Other types of toxicity tests • Specific tests: • reproductive studies, effect of a drug on the reproductive process • mutagenicity test: genetic damage, • carcinogencity test: neoplastic change, • skin sensitization test: drug’s irritancy • The test should be carried out in compliance for Good Laboratory Practice (GLP) for drug approval

  11. GENETICS • Other than dose, factor that influence the body response to drugs: idiosyncratic (occurring for no known reason) • affects pharmacodynamic and pharmacokinetic, e.g. normal difference within a species, between genders and strains, also, ‘abnormal’ genetic expression occurs • disparate response of different species to a drug: e.g. LD50 of ipomeanol, rat- 12 mg/kg, hamster- 140 mg/kg; • thalidomide, rat- insensitive, New Zealand white rabbits -sensitive; • strain difference, hexobarbital, sleeping time, A/NC- 48 min, SWR/HeN- 18 min

  12. Normal distribution, hyporeactive, average response, hyperreactive, e.g. coumadine, variation of 20 fold range, from bleeding to refractory,

  13. Population distribution curve sometimes becomes bimodal or multimodal, e.g. [ isoniazid] in plasma, statistically separated populations, left and right are fast and slow metabolizers, respectively.

  14. Primaquine sensitivity • Another genetically predisposed toxic reaction to drug • Primaquine (an antimalarial drug) or other oxidant drugs, hemolytic anemia, X chromosome genetic alteration , G6PDH (glucose 6-phosphate dehydrogenase) paucity in erythrocytes • G6P + G6PDH 6-phosphogluconolactone + NADPH 2NADPH + GSSG  2GSH + 2NADP, • fail to replenish NADPH and GSH  red blood cells damage • [G6PDH] in erythrocytes, trimodal distribution - 1. normal; 2. female carrier (heterozygous); 3. male carrier,

  15. Succinylcholine apnea • Another example of “abnormal” gene expression • Succinylcholine (muscle relaxant, reduce skeletal muscle rigidity during operation), • normal duration of action is of minutes; people with the atypical enzyme : hrs, abnormal duration, atypical serum cholinestrase, • dibucaine number : an assay for the atypical enzyme carrier, benzoylcholine (substrate), dibucaine (competitor), % inhibition of benzoylcholine hydrolysis • trimodal distribution (20, 60 and 80% inhibition), in carriers, less inhibition,

  16. GENDER • ethanol consumption, first-pass metabolism, in female LDH lower, • dinitrotoluene-induced hepatic tumor, higher incidence in male: male glucuronide conjugation, biliary excretion, hydrolyzed and reabsorption; urinary excretion predominates in female  better clearance; • chloroform-induced kidney damage, higher incidence in male : androgen effect, testosterone-mediated, castration diminished

  17. AGE • age related change: 1. liver metabolism; 2. renal elimination; 3. body composition • liver metabolism- less amount of drug metabolizing enzymes in newborn infants. • Therapeutic disorders • (1) gray baby syndrome : inadequate glucuronidation of chloramphenicol  [chloramphenicol]  • (2) sulfonamide induced kericterus: displacement of bilirubin from plasma by sulfonamide; • In general, reduced binding of drug to plasma proteins in neonatal period.

  18. Examples of paradoxical pharmacodynamic differences. antihistamine / barbiturates: sedation in adults, hyper-excitation in children  differences in receptor-mediated signal transudction • renal function- lower in neonates, blood flow approx. 8 folds during 1-2 y of birth, development of glomerulus, GFR  during first several weeks of life  antibiotic (e.g. getamicin) half-life , clearance rate .

  19. In elderly (geriatric pharmacology) • Declined physiological function during aging process, • total body water , liver mass , blood flow , % body fate , • after 40 y, liver mass  1% / y, after 30 y, cardiac output  1% /y, • Vd of water soluble drug , e.g. acetaminophen, alcohol, digoxin; drug sensitivity  because of [drugs] 

  20. elderly (cont.) • Vd of fat soluble drug  e.g. valium [valium] in serum , but because of pharmacodynamic change  Valium depression • serum albumin  , affecting protein bound drugs, highly protein bound drugs, e.g. sulfonylurea (an oral hypoglycemic drug)  any drug displaces the drug may lead to toxicity • Pharmacodynamic response change, e.g. b-receptor; b -agonists sensitivity  , may be due to c-AMP 

  21. ALLERGY • not follow dose-response relationship • e.g. chronic beryllium disease, hypersensitivity lung disorder, exposure to beryllium, lack of dose-response relationship

  22. characteristics of various drug side effects

  23. allergic reactions, immune response • antigens of large molecules; drugs only of 250-500 daltons, carrier proteins, hapten -an antigenic determinant ( epitope). • e.g. penicillin, penicilloyl groups, initial exposure, 7-10 d, period of sensitization.

  24. Various types of allergic reactions • Type I. Immediate immune response, IgE fixed mast cells and basophiles, IgE-hapten-protein complex •  release of mediators (e.g. histamine, heparin and tryptase and leutotrienes, prostaglandins and cytokines) •  bronchiolar constriction, capillary dilation or urticaria, severe episode-life threatening anaphylaxis

  25. Type II, cytotoxic response, • binding of IgG, IgA and IgM, activation of complement, target of cytotoxic reactions: cells in circulatory system, • e.g. methyldopa and quinidine - induced hemolytic anemia, thrombocytopenia.

  26. Type III, immune complex-mediated, deposition of hapten-protein-Abs (IgG) complex in vascular endothelium, subsequent complex fix, neutrophils attracted to phagocytize the complexes and liberate enzyme, damage vascular walls inflammation (serum sickness), • symptoms : e. g. fever, swelling lymph nodes, arthritis, nephritis and neruopathy, • drugs in risk e.g. sulfonamides, penicillins and anticonvulsants

  27. Type IV, cell-mediated response, • delayed reaction to the Ag , activated T-lymphocytes generated, release lymphokines activate macrophages neutrophiles, infiltration of these cells into organ, e.g. halothane-induced hepatitis

  28. Antihistamines • Histamine, • mediator of allergic reaction, receptors H1,2, 3- distinct effects via the various receptors, • histidine, decarboxylation, complex with heparin or chondroitin sulfate, stored as granules, body-wide distribution, concentrated in skin, lung and GI mucosa, • cimetidine, H2 blocker, gastric acid secretion inhibitor;

  29. Antihistamine : referred to H1 antagonist anti- ( urticaria, hay fever, insect bites) • antiemetic, anti-motion sickness, antiparkinsonism, antitussive, • old generation of antihistamines have side effects [blocker of cholinergic muscarinic receptor]: sedation ( used in OTC sleeping pills)

  30. Immune-related drug effects • glucocorticoids or azathioprine (prevent organ rejection), tumor incidence  • others modifying the antigenic properties of endogenous molecules without binding, e.g., hydralazine [antihypertensive] induce autoimmune e.g. SLE disorder

  31. Primary mechanisms of direct drug-induced cell injury • biochemical lesion: initial metabolic alteration  morphological change • (1) covalent binding • (2) lipid peroxidation • (3) oxidative stress

  32. Covalent binding • bioactivation, covalent bonds with endogenous macromolecules e.g. halothane [anesthetic], 2 types hepatotoxicity: one is direct cytotoxicity, the other is immune-related, • another example acetaminophen, oxidation product NAPQI [N-acetyl-p-benzoquinoneimine], conjugation with GSH, overdose, Phase II enzymes saturated,  covalent linked with proteins e.g. p58 (sensor for homeostasis); immune-related response may occur also.

  33. Lipid peroxidation • free radical, electrophilic species, O2 superoxide anion, polyunsaturated fatty acids in membrane undergo lipid peroxidation cellular injury

  34. Oxidative stress • superoxide anion radical, hydrogen peroxide, enzymes to clear the reactive oxygen species: superoxide dismutase, catalase, peroxidase • oxidation stress  depletion of cellular reducing agents (e.g. thiols, and NADP/NADPH) can lead to cell necrosis or apoptosis

  35. Teratogenesis • thalidomide- effects on development of embryo, • alcohol- CNS dysfunction: mental retardation, long-lasting effects • diethylstibestrol (was used for miscarriage prevention)- carcinogenesis, cervical and vaginal carcinoma found in daughters of treated mothers • Sadly, DES did not prove efficacious in miscarriage prevention

  36. Recent teratogenes • isotretoin [for acne] and etretinate [for psoriasis]-synthetic retinoids (vitamin A deriv.) • isotretoin-category X [contraindication for use during pregnancy]; physicians unnoticed the warning label until the problem broke out. • etretinate- serum concentration may last long 2 years, extended period of toxicity

  37. Bendectin story • antinausea • a report 1979 concerned bendectin’s 80% increase of risk in congenital effects of heart disease • 1983, removed from market by the company • further studies  only 0.89% risk • hospital admission due to excessive vomiting 

  38. Treating Drug Overdose • Drug responsible for poisonings: analgesic, antidepressants, sedative/hypnotics, stimulants and street drugs • American Association of Poison Control Centers, ingestion the most likely route (75%): accidental or intentional

  39. Aspirin • before 1972, aspirin the most frequent in child-poisioning • Poison prevention packaging act, 1970, children-resistant closures • numbers of death (19721989)  from 46 to 2

  40. Iron supplements • iron deficiency anemia • FDA required :iron tablets wrapped and capsules individually, time and dexterity discouraging young child

  41. Age-related drug poisoning • Intentional poisoning in adolescents (11-17) • elderly: 64 y older, dementia and confusion, improper use or storage, serum albumin and GFR , drug displacement

  42. Management trends • initial decontamination; • enhanced elimination; • specific antidote administration

  43. Initial decontamination • Ipecac syrup, chemoreceptor trigger zone in brain, local irritation of GI tract (gastric lavage ), contraindications with coma or convulsions, ingestion of corrosive substances, impaired gag reflex, • followed by activated charcoal, high adsorptive capacity, 60% if simultaneous administration, 9% if 3 h delay

  44. Enhanced elimination- facilitated renal excretion or extracorporeal methods • facilitated renal excretion: fluid diuresis, excess fluid, ionized diuresis,  or  urine pH • extracorporeal methods -dialysis or hemoperfussion for coma

  45. Specific antidote administration • Naloxone competes for m and k opoid receptors, reverse sedation and respiratory depression of morphine-like drugs • N-aceylcysteine (NAC) e.g. acetaminophen overdose, provides -SH groups • deferoxamine- for iron poisoning, an chelator • Ab e.g. digoxin-specific Fab antibody

  46. The single most important treatment of poisoned patients is supportive care. You must treat patient not the poison

  47. 11/5 mid-term exam, covering the first 4 lectures

More Related